Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. Patients with HER2-positive advanced G/GEJ cancer refractory to first-line chemotherapy with trast...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2020-06, Vol.38 (17), p.1919-1927
Hauptverfasser:	Makiyama, Akitaka, Sukawa, Yasutaka, Kashiwada, Tomomi, Kawada, Junji, Hosokawa, Ayumu, Horie, Yoshiki, Tsuji, Akihito, Moriwaki, Toshikazu, Tanioka, Hiroaki, Shinozaki, Katsunori, Uchino, Keita, Yasui, Hirofumi, Tsukuda, Hiroshi, Nishikawa, Kazuhiro, Ishida, Hiroyasu, Yamanaka, Takeharu, Yamazaki, Kentaro, Hironaka, Shuichi, Esaki, Taito, Boku, Narikazu, Hyodo, Ichinosuke, Muro, Kei
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Esophageal Neoplasms - drug therapy Esophageal Neoplasms - enzymology Esophageal Neoplasms - pathology Esophagogastric Junction - enzymology Esophagogastric Junction - pathology Female Humans Male Middle Aged Paclitaxel - administration & dosage Paclitaxel - adverse effects Paclitaxel - therapeutic use Progression-Free Survival Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - blood Stomach Neoplasms - drug therapy Stomach Neoplasms - enzymology Stomach Neoplasms - pathology Trastuzumab - administration & dosage Trastuzumab - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!